Phaseline

Targets › MPC1

MPC1 (Mitochondrial pyruvate carrier 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Sep 2028.

Mediates the uptake of pyruvate into mitochondria to maintain the balance between glycolysis and oxidative phosphorylation. Plays an essential role in cellular metabolism. (UniProt, Q9Y5U8)

Open in Phaseline: the race on MPC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of VirginiaCIR-0602K
mitochondrial pyruvate carrier (MPC) inhibitor
MPC1, MPC2Phase 2Type 1 Diabetes (T1D)Sep 2028

Conditions

Type 1 Diabetes (T1D) (1)

Modalities

small molecule (1)

Companies

University of Virginia (1)

Related targets

MPC2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.